BR112023000711A2 - Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco - Google Patents
Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármacoInfo
- Publication number
- BR112023000711A2 BR112023000711A2 BR112023000711A BR112023000711A BR112023000711A2 BR 112023000711 A2 BR112023000711 A2 BR 112023000711A2 BR 112023000711 A BR112023000711 A BR 112023000711A BR 112023000711 A BR112023000711 A BR 112023000711A BR 112023000711 A2 BR112023000711 A2 BR 112023000711A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- drug conjugate
- conjugate composition
- producing
- antibodies
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 5
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 4
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
MÉTODO PARA PRODUZIR UMA COMPOSIÇÃO DE CONJUGADO DE ANTICORPO-FÁRMACO, E, COMPOSIÇÃO DE CONJUGADO DE ANTICORPO-FÁRMACO. Um método para produzir uma composição de conjugado de anticorpo-fármaco incluindo (i) uma etapa para fazer com que os anticorpos reajam com um agente redutor e obter anticorpos tendo um grupo tiol, seguido por (ii) uma etapa para fazer com que os anticorpos tendo um grupo tiol obtido na etapa (i) reajam com um intermediário de ligante de fármaco, o método para produzir sendo distinguido em que a etapa (i) é realizada até que a razão de constituição de anticorpos tendo quatro tióis intercadeia pesada-leve e a razão de constituição de anticorpos tendo quatro tióis intercadeia pesada-pesada atinjam valores constantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020122695 | 2020-07-17 | ||
PCT/JP2021/026784 WO2022014698A1 (ja) | 2020-07-17 | 2021-07-16 | 抗体-薬物コンジュゲートの製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000711A2 true BR112023000711A2 (pt) | 2023-01-31 |
Family
ID=79555679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000711A BR112023000711A2 (pt) | 2020-07-17 | 2021-07-16 | Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230277679A1 (pt) |
EP (1) | EP4183799A1 (pt) |
JP (1) | JPWO2022014698A1 (pt) |
KR (1) | KR20230041023A (pt) |
CN (1) | CN116157417A (pt) |
AU (1) | AU2021307257A1 (pt) |
BR (1) | BR112023000711A2 (pt) |
CA (1) | CA3186205A1 (pt) |
IL (1) | IL299803A (pt) |
TW (1) | TW202216212A (pt) |
WO (1) | WO2022014698A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
CN117180449B (zh) * | 2023-11-03 | 2024-04-02 | 正大天晴药业集团南京顺欣制药有限公司 | 抗体药物偶联物的制备方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
AU9124801A (en) | 2000-09-28 | 2002-04-08 | Oracle Corp | Enterprise web mining system and method |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
US6724969B2 (en) | 2001-08-03 | 2004-04-20 | Photon-X, Inc. | Method of fabricating polymer optical channel waveguides with multiple types of waveguide core materials |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US7069244B2 (en) | 2002-09-17 | 2006-06-27 | First Data Corporation | Method and system for merchant processing of purchase card transactions with expanded card type acceptance |
KR100552478B1 (ko) | 2003-11-20 | 2006-02-15 | 삼성전자주식회사 | 파워 인렛 소켓 |
EP1725586B1 (en) | 2004-03-02 | 2015-01-14 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
ITMI20042455A1 (it) | 2004-12-22 | 2005-03-22 | Sued Chemie Mt Srl | Procedimento per la rimozione di ossidi di azoto con materiale absorbente di ossidi stessi |
WO2008033891A2 (en) | 2006-09-12 | 2008-03-20 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Azonafide derived tumor and cancer targeting compounds |
KR20220035504A (ko) | 2008-04-30 | 2022-03-22 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
KR20100137585A (ko) | 2008-04-30 | 2010-12-30 | 이뮤노젠 아이엔씨 | 강력한 복합체 및 친수성 링커 |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
AU2011239525B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
AU2011239522B2 (en) | 2010-04-15 | 2014-10-23 | Medimmune Limited | Targeted pyrrolobenzodiazapine conjugates |
EA036202B1 (ru) | 2011-10-14 | 2020-10-14 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
KR102087017B1 (ko) | 2012-10-11 | 2020-03-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
WO2014107024A1 (ko) | 2013-01-03 | 2014-07-10 | 셀트리온 | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
WO2014134457A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
CN105188766B (zh) | 2013-03-15 | 2019-07-12 | 瑞泽恩制药公司 | 生物活性分子、其偶联物及治疗用途 |
EP3088419B1 (en) | 2013-12-25 | 2018-10-10 | Daiichi Sankyo Company, Limited | Anti-trop2 antibody-drug conjugate |
BR112017027690A2 (pt) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
EP3677589A4 (en) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
EP3828206A4 (en) * | 2018-07-25 | 2022-04-20 | Daiichi Sankyo Company, Limited | METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE |
-
2021
- 2021-07-16 TW TW110126218A patent/TW202216212A/zh unknown
- 2021-07-16 WO PCT/JP2021/026784 patent/WO2022014698A1/ja unknown
- 2021-07-16 IL IL299803A patent/IL299803A/en unknown
- 2021-07-16 US US18/016,308 patent/US20230277679A1/en active Pending
- 2021-07-16 KR KR1020237005156A patent/KR20230041023A/ko unknown
- 2021-07-16 EP EP21841453.0A patent/EP4183799A1/en active Pending
- 2021-07-16 BR BR112023000711A patent/BR112023000711A2/pt unknown
- 2021-07-16 CA CA3186205A patent/CA3186205A1/en active Pending
- 2021-07-16 JP JP2022536458A patent/JPWO2022014698A1/ja active Pending
- 2021-07-16 AU AU2021307257A patent/AU2021307257A1/en active Pending
- 2021-07-16 CN CN202180060157.1A patent/CN116157417A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230041023A (ko) | 2023-03-23 |
JPWO2022014698A1 (pt) | 2022-01-20 |
CA3186205A1 (en) | 2022-01-20 |
WO2022014698A1 (ja) | 2022-01-20 |
TW202216212A (zh) | 2022-05-01 |
AU2021307257A1 (en) | 2023-03-09 |
EP4183799A1 (en) | 2023-05-24 |
IL299803A (en) | 2023-03-01 |
US20230277679A1 (en) | 2023-09-07 |
CN116157417A (zh) | 2023-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023000711A2 (pt) | Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco | |
BR112018068986A2 (pt) | composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips | |
PE20220220A1 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica | |
BRPI0409342A (pt) | pelìcula de gel termorreversìvel homogênea, cápsulas moles, processos para fabricar as pelìculas de gel e para fabricar cápsulas moles contendo as pelìculas de gel, e, forma sólida | |
BR112017027690A2 (pt) | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco | |
BR0017031A (pt) | Composições de perfume com viscosidade intensificada e processo para a sua preparação | |
CL2019002472A1 (es) | Composiciones de biomasa que contienen pectina activada, productos y métodos de producción (divisional solicitud 201902256) | |
BR0300846A (pt) | Processo para produzir nanopartìculas de paclitaxel e albumina | |
BR112022024833A2 (pt) | Conjugados anticorpo anti-bcma-fármaco e métodos de uso | |
BR112022011032A2 (pt) | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo | |
JOP20210269A1 (ar) | تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها | |
BR112013032777A2 (pt) | composição de sapogenol de soja | |
BR112023022098A2 (pt) | Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos | |
BR112022003443A2 (pt) | Processo de preparação de composição de mistura asfáltica, composição de mistura asfáltica, uso de uma composição de mistura asfáltica | |
BRPI0800109A (pt) | método para remodelar, de modo permanente, as fibras de queratina, e, uso de uma composição oxidante | |
AR109378A1 (es) | Composición para geles de baño | |
CO2024002924A2 (es) | Nanopartícula para el desarrollo temprano de la resistencia del concreto, composición para formar el concreto, que incluye la misma, y método para producir la misma | |
BR112022021034A2 (pt) | Formulações solúveis em água contendo canabinóides | |
BR112021024233A2 (pt) | Implante para fixar um tendão ou um ligamento a um tecido duro compreendendo um eixo, primeiros pilares para entrar em contato com um tecido duro, e segundos pilares para entrar em contato com um tendão ou um ligamento | |
BRPI0408056A (pt) | uma composição de emulsão, um método para preparar uma composição de emulsão, uso de uma composição | |
BR0113690A (pt) | Método para preparar uma composição condicionadora de tecido, e, composição condicionadora de tecido | |
BR112022015751A2 (pt) | Revestimento | |
BR112019003298A2 (pt) | composição para cuidados pessoais, e, formulação para banho. | |
BR112022026485A2 (pt) | Composição, processo para tingimento ou descoloração de fibras de queratina, usos de uma composição e dispositivo de múltiplos compartimentos | |
BR112022001504A2 (pt) | Composto |